Clinical Trial Update: A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants [Phase 1]

View source ↗

Summary

Phase 1 open-label study to evaluate pharmacokinetics and potential drug-drug interactions of ENV-101 (taladegib) in healthy participants. Idiopathic Pulmonary …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ENV-101 (taladegib) (taladegib)

Snippet

Sponsor: Endeavor Biomedicines, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 1 | Status: NOT_YET_RECRUITING